• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Rapport Therapeutics Stock In Focus After $350 Million Capital Raise

    Simply Wall St·11/10/2026 12:25:56
    Listen to the news
    • Rapport Therapeutics completed a follow on equity offering of about US$200 million and a US$150 million convertible note issue, alongside reporting third quarter 2026 net loss of US$40.24 million and nine month loss of US$116.71 million.
    • The combined equity and convertible debt raises reshape Rapport Therapeutics' funding mix, which could influence how investors view dilution, interest costs and cash runway in relation to its ongoing central nervous system pipeline.
    • We will now examine how this sizeable capital raise through equity and convertible notes could reshape Rapport Therapeutics' investment narrative.
    Spot 36 healthcare AI stocks that, like Rapport Therapeutics, are raising capital to fund central nervous system research and could be primed for the next wave of attention.

    Rapport Therapeutics Investment Narrative Recap

    To own Rapport Therapeutics, you need to believe its precision neuroscience platform can turn RAP-219 and the wider central nervous system portfolio into meaningful future products despite ongoing losses. The analyst consensus Narrative on Simply Wall St highlights heavy dependence on RAP-219 epilepsy and bipolar mania data as the core driver. The latest quarter shows a net loss of US$40.24 million, which keeps the focus squarely on execution, trial progress and careful spend.

    In the short term, the most important catalyst remains clinical readouts from RAP-219, including the pivotal-like bipolar mania Phase 2 and global epilepsy Phase 3 trials. The biggest risk is that current loss levels, US$116.71 million over nine months, continue while timelines slip, which could strain the cash runway even after the fresh equity and convertible funding. The recent financing changes the balance sheet mix but does not change that core risk reward equation.

    The completed US$199.99882 million follow-on equity offering is the announcement that ties most directly to the current story. It sits alongside the US$150 million 2.25% convertible notes due 2032, and together these deals reshape how Rapport Therapeutics funds the Phase 3 epilepsy program and broader CNS pipeline. For readers, this is essentially about trading dilution today for a longer attempt at future value creation.

    This capital raise connects directly to the catalysts flagged in the analyst consensus Narrative on Simply Wall St. RAP-219 advancement in epilepsy, bipolar mania and the long-acting injectable program all require sustained spend while the group is still loss-making and not forecast to be profitable over the next three years. Extra funding can support those programs, but equity issuance and new convertibles also sit alongside existing risks around earnings decline forecasts and ongoing shareholder dilution.

    Rapport Therapeutics' narrative projects US$8.1 million revenue and US$1.4 million earnings by 2029. This projection is based on analysts assuming revenue will decline 26.0% per year and implies an earnings swing of about US$151.9 million from the current US$150.5 million loss.

    Uncover how Rapport Therapeutics' fair value indicates a 147% potential upside to its current price, a gap that could narrow as sentiment shifts.

    NasdaqGM:RAPP 1-Year Stock Price Chart
    NasdaqGM:RAPP 1-Year Stock Price Chart

    Exploring Other Perspectives

    The two fair value estimates from the Simply Wall St Community cluster tightly around US$64.21 to US$64.43, which shows how some private investors model Rapport Therapeutics on their own numbers. Your view might differ once you factor in the RAP-219 trial reliance, ongoing losses, and fresh equity plus convertible funding.

    Explore another Rapport Therapeutics fair value estimate, including one that suggests up to 147% upside from the current price.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond Rapport Therapeutics?

    If you want to put Rapport Therapeutics in context, it can help to line it up against a broader watchlist of opportunities with different risk and balance sheet profiles.